Product Pipeline

Specialty biosimilars in development

Valerius is developing specialty biosimilars for global markets according to the strict directions from US and EU regulatory bodies.

Our first biosimilar candidates are currently in early pre-clinical development and include monoclonal antibodies, enzymes and fusion proteins covering different therapeutic areas such as oncology, inflammation, ophthalmology and respiratory.


The development of our future pipeline candidates is planned to commence in 2022.

We use cookies to improve your user experience. By continuing to browse the site you are giving your consent for us to set cookies. If you don't agree, you can find here further informations.

OK, I agree.